Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF–caspase 8–GSDMD/E axis in ovarian cancer

1 Oct 2024

Abstract excerpt

Background In addition to their established action of synthetic lethality in tumor cells, poly(ADP-ribose) polymerase inhibitors (PARPis) also orchestrate tumor immune microenvironment (TIME) that contributes to suppressing tumor growth. However, it remains not fully understood whether and how PARPis trigger tumor-targeting immune responses. Methods To decode the immune responses reshaped by PARPis, we conducted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Inflammasome and immune disorders
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39366751
DOI: 10.1136/jitc-2024-009032

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF–caspase 8–GSDMD/E axis in ovarian cancerPMID 39366751Read ↗

The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancersSemantic proximity Read ↗

Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumorsSemantic proximity Read ↗

Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectivesSemantic proximity Read ↗

Mitigating T cell DNA damage during PARP inhibitor treatment enhances antitumor efficacySemantic proximity Read ↗

Mechanism and regulation of pyroptosis-mediated in cancer cell deathSemantic proximity Read ↗

Role of Pyroptosis in Gynecological Oncology and Its Therapeutic RegulationSemantic proximity Read ↗

Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.Semantic proximity Read ↗

Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical ImplicationsSemantic proximity Read ↗

Impact of Caspase3/GSDME-Mediated Pyroptosis on Tumor Immune Microenvironment and Clinical Prognosis Across Multiple CancersSemantic proximity Read ↗

Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune systemSemantic proximity Read ↗

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint InhibitorsSemantic proximity Read ↗

PARP inhibitors elicit a cellular senescence mediated inflammatory response in homologous recombination proficient cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.